[
    [
        {
            "time": "",
            "original_text": "泰格医药(03347.HK)回购注销2.56万股限制性股票",
            "features": {
                "keywords": [
                    "泰格医药",
                    "回购",
                    "注销",
                    "限制性股票"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)回购注销2.56万股限制性股票",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药行业深度：医保谈判 扰动创新药市场变革",
            "features": {
                "keywords": [
                    "医保谈判",
                    "创新药",
                    "市场变革"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业深度：医保谈判 扰动创新药市场变革",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业点评：药械板块短期受政策影响 CXO板块相对稳健",
            "features": {
                "keywords": [
                    "药械板块",
                    "政策影响",
                    "CXO板块",
                    "稳健"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业点评：药械板块短期受政策影响 CXO板块相对稳健",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【新康界每周投资策略】科创板细则落地，或可分拆上市的医药上市公司有哪些？",
            "features": {
                "keywords": [
                    "科创板",
                    "细则落地",
                    "分拆上市",
                    "医药上市公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【新康界每周投资策略】科创板细则落地，或可分拆上市的医药上市公司有哪些？",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【新康界每周投资策略】医药生物行业分析系列——制药研发外包CRO",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业分析",
                    "CRO",
                    "制药研发外包"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【新康界每周投资策略】医药生物行业分析系列——制药研发外包CRO",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "集采后仿制药利润大幅“割肉”，药企能否抓住创新药时代风口",
            "features": {
                "keywords": [
                    "集采",
                    "仿制药",
                    "利润下降",
                    "创新药",
                    "风口"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "集采后仿制药利润大幅“割肉”，药企能否抓住创新药时代风口",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【行情】港股医药股造好，中国生物科技服务涨15%，远大医药、百济神州、泰格医药涨3%",
            "features": {
                "keywords": [
                    "港股",
                    "医药股",
                    "造好",
                    "中国生物科技服务",
                    "远大医药",
                    "百济神州",
                    "泰格医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【行情】港股医药股造好，中国生物科技服务涨15%，远大医药、百济神州、泰格医药涨3%",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药股造好，中国生物科技服务涨15%",
            "features": {
                "keywords": [
                    "医药股",
                    "造好",
                    "中国生物科技服务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药股造好，中国生物科技服务涨15%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]